Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals
Open Access
- 4 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infectious Diseases and Therapy
- Vol. 9 (4), 837-849
- https://doi.org/10.1007/s40121-020-00334-1
Abstract
Background Serology testing is explored for epidemiological research and to inform individuals after suspected infection. During the coronavirus disease 2019 (COVID-19) pandemic, frontline healthcare professionals (HCP) may be at particular risk for infection. No longitudinal data on functional seroconversion in HCP in regions with low COVID-19 prevalence and low pre-test probability exist. Methods In a large German university hospital, we performed weekly questionnaire assessments and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) measurements with various commercial tests, a novel surrogate virus neutralisation test, and a neutralisation assay using live SARS-CoV-2. Results From baseline to week 6, 1080 screening measurements for anti-SARS CoV-2 (S1) IgG from 217 frontline HCP (65% female) were performed. Overall, 75.6% of HCP reported at least one symptom of respiratory infection. Self-perceived infection probability declined over time (from mean 20.1% at baseline to 12.4% in week 6, p < 0.001). In sera of convalescent patients with PCR-confirmed COVID-19, we measured high anti-SARS-CoV-2 IgG levels, obtained highly concordant results from enzyme-linked immunosorbent assays (ELISA) using e.g. the spike 1 (S1) protein domain and the nucleocapsid protein (NCP) as targets, and confirmed antiviral neutralisation. However, in HCP the cumulative incidence for anti-SARS-CoV-2 (S1) IgG was 1.86% for positive and 0.93% for equivocal positive results over the study period of 6 weeks. Except for one HCP, none of the eight initial positive results were confirmed by alternative serology tests or showed in vitro neutralisation against live SARS-CoV-2. The only true seroconversion occurred without symptoms and mounted strong functional humoral immunity. Thus, the confirmed cumulative incidence for neutralizing anti-SARS-CoV-2 IgG was 0.47%. Conclusion When assessing anti-SARS-CoV-2 immune status in individuals with low pre-test probability, we suggest confirming positive results from single measurements by alternative serology tests or functional assays. Our data highlight the need for a methodical serology screening approach in regions with low SARS-CoV-2 infection rates. Trial Registration The study is registered at DRKS00021152.Funding Information
- Novartis Pharma (MAIN457A-FVKH012)
- Deutsches Zentrum für Infektionsforschung (Infrastrukturförderung)
- PARI (Grant)
- Verein Kinderherz Hannover (Grant)
This publication has 38 references indexed in Scilit:
- Virological assessment of hospitalized patients with COVID-2019Nature, 2020
- Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front LineThe New England Journal of Medicine, 2020
- Patients with RT-PCR-confirmed COVID-19 and Normal Chest CTRadiology, 2020
- Presumed Asymptomatic Carrier Transmission of COVID-19JAMA, 2020
- Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Covid-19: four fifths of cases are asymptomatic, China figures indicatePublished by BMJ ,2020
- Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020Eurosurveillance, 2020
- Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019JAMA Network Open, 2020
- Middle East Respiratory Syndrome Coronavirus Infections in Health Care WorkersThe New England Journal of Medicine, 2013
- Cluster of severe acute respiratory syndrome cases among protected health-care workers--Toronto, Canada, April 2003.2003